FDA Approves Pill Version Of Novo Nordisk’s Wegovy, Possibly Widening Access

The Food and Drug Administration on Monday approved the oral version of Novo Nordisk’s injectable weight loss drug Wegovy, making it the first GLP-1 pill to be cleared by regulators for obesity and possibly allowing many more Americans to access a highly effective treatment.

The Wegovy pill, whose approval for weight loss was widely anticipated, has also been approved to reduce cardiovascular risks, similar to the injectable version.

Novo plans to launch the drug in January. In a late-stage study, the highest dose that will be sold, 25 milligrams, led patients to lose about 14% of their weight, similar to the efficacy seen with injectable Wegovy.

Novo did not immediately release details on pricing.

Injectable Wegovy, along with Eli Lilly’s injectable drug Zepbound, has already seen immense demand. Novo argues that there could be even more interest in a GLP-1 pill, since it could be more convenient to take and can be distributed without cold storage. (Novo already sells Rybelsus, a GLP-1 pill containing the same ingredient, but it’s approved only to treat type 2 diabetes.)

The approval comes as Novo has been struggling to recoup its lead in the obesity market, as more patients gravitate towards Lilly’s Zepbound than injectable Wegovy. It’s not yet clear whether the oral version will significantly boost Novo’s market share and expand access for Americans.

Novo’s pill consists of large molecules called peptides, making it harder for the body to absorb and thus requiring a large amount of pharmaceutical ingredients to be effective. It also must be taken by patients in the morning at least 30 minutes before any food.

Lilly, meanwhile, has developed its own GLP-1 pill called orforglipron, which is currently under FDA review and is expected to be approved in the next few months. Orforglipron is a small molecule, which experts say could make it easier to manufacture. It doesn’t carry restrictions around when patients need to take it, but it didn’t show as much efficacy in its trials as oral Wegovy.

Pricing will also be a significant factor affecting demand. Novo and Lilly have already reached an agreement with the Trump administration to sell their pills, once approved, at $150 a month for the lowest dose through direct-to-consumer channels, in which patients pay cash prices without using insurance. That’s lower than the cash price for low-dose injectables, but the drugmakers haven’t indicated what they will ultimately charge for higher doses of the pills or what they’ll charge payers.

 

Source Link

Recommended Articles

CMS Distributes $10B To Strengthen Rural Health Care Access

The Centers for Medicare & Medicaid Services will distribute $10 billion among all 50 states during the second year of the Rural Health Transformation Program. This funding is intended to build on early progress and deliver lasting improvements in access, quality and health outcomes for rural Americans. “President Trump made a historic investment in rural ...

Read More

What Your Health Benefits Advisor Wishes You Knew Before Choosing A Plan

A family can pay their health insurance premium every month and still hesitate to see a doctor because of what the visit might cost. Or worse, an employee may believe the plan they chose through their company covers a specialist, only to learn it does not once they are at the provider’s office. Misunderstandings can ...

Read More

Feds Invite Industry To Test Electronic Prior Auth Readiness

The federal government is inviting health insurance companies, hospitals and electronic health record companies to test their readiness for upcoming electronic prior authorization requirements. The Office of the National Coordinator for Health Information Technology, the Health and Human Services Department and the Centers for Medicare and Medicaid Services announced Thursday they will hold voluntary 10-12 ...

Read More

Google Cloud Rolls Out Gemini For Healthcare

Google launched Tuesday Gemini for healthcare, an agentic artificial intelligence platform aimed at connecting complex clinical, financial and administrative workflows used by healthcare providers and payers. The platform was developed alongside clinical and health plan leaders and is built to support HIPAA compliance, the tech giant said. “The fundamental challenge in healthcare isn’t a lack ...

Read More
arrowcaret-downclosefacebook-squarehamburgerinstagram-squarelinkedin-squarepauseplaytwitter-squareyoutube-square